increase to 20% or more in patients older than 60. 2 If growth factors could decrease the incidence of bacterial and fungal infections, then perhaps treatment outcomes would improve with less induction deaths and more complete remissions (CRs).
Multiple prospective, randomized, placebo-controlled trials have been conducted with GM-CSF [3] [4] [5] [6] [7] and G-CSF 8-13 administered after chemotherapy in patients with newly diagnosed AML to test this hypothesis ( Table 1) . Comparison among these studies is difficult, owing to design variability, especially because some clinicians used growth factors only after chemotherapy to evaluate their effectiveness in attenuating neutropenia, whereas others used them before, during, and after chemotherapy to evaluate any additional benefits of a priming strategy.
Of 13 randomized trials, all but one small study 7 showed a statistically significant reduction in the duration of neutropenia by 2 to 7 days with growth factor support either during or after chemotherapy. This shortened period of neutropenia modestly decreased duration of infection and antibiotic and antifungal use, and in some trials decreased hospitalization.
8,10,11,13
Despite a consistent reduction in duration of neutropenia in these studies, only the ECOG 6 trial showed that accelerated neutrophil recovery lowered the rate of documented infection. In this trial, GM-CSF in patients older than 55 years was associated with fewer grade 4/5 documented infections (P = .02) and deaths from grade 3/4 pneumonia. This led to the approval of GM-CSF in patients with AML. 6 Cost-effective analyses have yielded mixed results, with 2 studies showing a cost savings of up to $2000 and 2 showing a cost increase. 14, 15 Disappointingly, a shorter duration of neutropenia had no effect on the end points of CR, overall survival (OS), or disease-free survival (DFS) in most of these studies. A few studies showed a statistically greater CR rate for patients in the growth factor arms, but this did not translate into improvement in OS or DFS. 8, 12 The aforementioned ECOG study by Rowe et al. 6 was the only one to show a survival benefit for the GM-CSF-treated group over placebo (median survival, 10.6 vs. 4.8 months; P = .021). However, the median survival in the placebo arm was substantially lower than that reported in other studies for the same age group. 3, 5, 8, 11, 12, 16 Growth factor support did not have a favorable impact on CR, 3, 5, 9, 11, 16, 17 OS, or DFS 3, 5, 8, 9, 11, 12, 16, 17 rates in older patients, for whom there was the greatest hope for impact.
Initially, when growth factors were introduced and contemplated for use in AML, experts were concerned that they would have detrimental effects based on substantial in vitro evidence that growth factors would stimulate persistent leukemia cells. Therefore, some studies delayed the administration of growth factor until a bone marrow aspirate/biopsy performed on day 10 showed marrow aplasia.
6,11 However, the reproducibility of the results (Table 1) shows that this may be unnecessary. Only the study by Zittoun et al. 7 showed a nonsignificant decrease in CR rate in patients randomized to GM-CSF.
Collectively, the data suggest that either G-CSF or GM-CSF can be given during or after chemotherapy without compromising CR, OS, or DFS rates. These agents seem safe and well tolerated during not only induction therapy but also consolidation therapy.
10,18 Because of the heterogeneity of studies, no clear consensus exists for their use, nor is one agent clearly superior to the other, because no large randomized trials have compared them directly. Both agents are approved for use in adults with AML (GM-CSF in patients > 55 years) in the United States. Despite a decrease in the duration of neutropenia, however, evidence suggests that growth factors in AML provide no clinical benefit. Therefore, routine use in supportive care for all patients undergoing therapy for AML is unwarranted.
Growth Factor Priming for Treatment
Growth factors have also been extensively studied to assess their efficacy in priming strategies. Only a small subset of leukemia blasts is clonogenic, meaning they have the ability to proliferate and form colonies. These clonogenic leukemia cells are relatively quiescent and are therefore immune to the S-phase-dependent mechanism of cell killing inherent to chemotherapeutic agents such as cytarabine. This population of quiescent leukemia cells thus represents a potential mechanism of resistance and relapse. In vitro studies show that co-culturing leukemia cells with GM-CSF, G-CSF, or interleukin 3 (IL-3) results in a higher proportion of cells entering S-phase. [19] [20] [21] [22] When used in combination with cytarabine, growth factors enhance the incorporation of cytarabine into the DNA of leukemia cells, which then confers a greater cytotoxic effect of cytarabine on clonogenic leukemia cells. Abbreviations: A, after chemotherapy; ANC, absolute neutrophil count; B, before chemotherapy; CR, complete remission; D, during chemotherapy; DFS, disease-free survival; EFS, event-free survival; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; OS, overall survival; RFS, relapse-free survival.
Early trials using GM-CSF or G-CSF in a priming strategy have confirmed that growth factor administration increases the recruitment of leukemia cells into S-phase. [23] [24] [25] Furthermore, some studies showed that the addition of a growth factor to chemotherapy correlated with response 24 and hinted at an improved CR rate compared with historical controls.
26,27 Larger randomized studies have been completed and a clear benefit of priming has not been identified in terms of OS, 5, 25, [28] [29] [30] although some studies show an improvement in DFS or event-free survival (EFS). 16, [31] [32] [33] [34] In one of the largest studies, Lowenberg et al. 31 randomized 640 patients between 18 and 60 years with newly diagnosed AML to receive 2 planned induction cycles with or without G-CSF priming. Notably, G-CSF was only administered the day before and during cytarabine administration in each cycle. No statistically significant difference was seen in CR rates between the G-CSF and control arms (79% vs. 83%; P = .24). At a median follow-up of 55 months, DFS was higher in the group that received G-CSF than in the control (42% vs. 33%; relative risk for relapse or death, 0.77; 95% CI, 0.62-0.96; P = .02). This was primarily because of a lower relapse rate in the G-CSF arm (46% vs. 54%; P = .04). However, at 4 years no statistically significant differences were seen between the groups in OS and EFS. A subgroup analysis showed that priming with G-CSF reduced the probability of relapse and improved overall survival among patients with standard-risk AML compared with the control arm (45% vs. 35%; P = .02), but had no effect for those in the AML groups with unfavorable risk; the number of patients in the favorable risk group was too low for any meaningful conclusions to be drawn.
Similarly, in another trial from France, 259 patients between 15 and 49 years with newly diagnosed AML were randomized to undergo a time-sequential induction regimen given alone or with GM-CSF priming.
32 GM-CSF was administered concomitantly with chemotherapy during induction and all cycles of consolidation. CR rates were significantly improved in the GM-CSF arm (88% vs. 78%; P < .04). At 3 years, similar to the Lowenberg et al. 4 trial, a trend was seen toward improvement in EFS for the GM-CSF-primed arm compared with the control (42% vs. 34%; P = .06), but no statistically significant difference occurred in OS. Again, in subgroup analysis, priming with GM-CSF improved EFS for those in the intermediaterisk category (P = .05). Preliminary data from the German AML Cooperative Group corroborate these results. 34 In this trial, patients underwent induction, consolidation, and maintenance therapy with or without priming with G-CSF. Again, no difference was seen in CR rate or relapse-free survival between the groups, but subgroup analysis showed a trend toward longer relapse-free survival for those with intermediate-risk cytogenetics and primed with G-CSF.
Overall, priming with growth factors seems to be well tolerated and does not have a negative impact on CR or OS, but this strategy is not without its flaws. In a few studies, treatment had to be interrupted secondary to leukocytosis. 31, 32 In the Lowenberg et al. 31 trial, more deaths occurred within 50 days after cycles 1 and 2 of chemotherapy in the G-CSF group compared with the control arm, but this did not result in a statistically significant difference in CR or OS between the groups. Another trial, comparing 3 different anthracyclines in combination with cytarabine during induction with or without GM-CSF in patients older than 55 years, showed that the priming strategy delayed the initiation of chemotherapy. 25 Patients who did not have a delay in chemotherapy had a higher CR rate than those who participated in the priming strategy (50% vs. 38%; P = .03).
Correlative studies have supported the rationale behind priming. Rowe et al. 25 collected samples at days 0 and 2 in 106 patients (53 placebo and 53 GM-CSF) to measure the mean change in S-phase percentage blasts. The mean change in S-phase percentage for the GM-CSF group was statistically significant higher than placebo (2.05% vs. 0.25%; P = .003), suggesting that GM-CSF priming resulted in a larger change in the S-phase percentage, as intended. However, the increase was minimal and did not differ between patients who experienced a CR and those who did not. Thus, the small change in S-phase percentage did not have a meaningful impact on important clinical end points. Data are lacking as to what effect priming has on the clonogenic leukemia cells.
ALL G-CSF and GM-CSF
Similar to AML, significant heterogeneity occurred in trials examining the role of growth factor support in ALL. Table 2 outlines the characteristics and main results of the major trials. For the most part, the benefits are similar to those seen in AML, and concern exists that growth factors would stimulate the leukemic clone. Many studies show a marked reduction in the duration of neutropenia during an initial induction and later consolidation phases.
The dose used is somewhat important. In one trial, 2, 5, or 10 mcg/kg/d doses of filgrastim were tested during induction and consolidation. 35 The 2 higher doses resulted in a shorter duration of neutropenia during induction compared with the lowest dose, whereas no difference occurred in neutrophil recovery in subsequent consolidation cycles among all 3. During consolidation, each dose was associated with faster neutrophil count recovery than in the control.
In one of the largest randomized, controlled trials in ALL, 198 patients were randomized to receive G-CSF 5 µg/kg/d starting on day 5 or placebo.
36
Patients who received G-CSF had a faster neutrophil count recovery during induction, higher CR (87% vs. 77%; P = .18), and fewer induction deaths (5% vs. 11%). Growth factors were used through 2 subsequent consolidation treatments and resulted in substantial decreases in time to neutrophil count recovery; however, G-CSF did not allow patients to complete the first 3 months of therapy any more quickly than on placebo. Furthermore, the higher CR rate did not translate into improved OS or DFS for the G-CSF Abbreviations: ANC, absolute neutrophil count; CR, complete remission; DFS, disease-free survival; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte macrophage colony-stimulating factor; NSS, not statistically significant; OS, overall survival.
arm compared with placebo after almost 5 years of follow-up.
Much research has evaluated the optimal timing of growth factors in relationship to chemotherapy in ALL. In ALL, chemotherapy is given in multiple divided doses over extended periods. A few studies have examined whether initiating a growth factor later after chemotherapy resulted in improved outcomes or cost savings. Growth factor support after chemotherapy reduces the duration of neutrophil recovery compared with historical controls, whether it is started within 5 to 7 (early) or 10 to 12 days (delayed) from the start of chemotherapy. 37, 38 Incidence and severity of infection did not differ between the early and delayed administration groups, and the delayed administration did not negatively impact CR rates. 37, 38 Additionally, in one study, patients in the delayed administration arm had 40% less G-CSF administered but remained in the hospital a median of 2 days more than the early group, so how much impact a delayed schedule has on the cost of growth factor support is unclear. 38 In another study, early (day 4) administration led to faster neutrophil recovery, less infectious complications, and less antibiotic and antifungal therapy than late (day 15) administration of G-CSF, but was associated with a higher cost.
39
Whether a benefit exists to a time-sequenced administration of growth factor and chemotherapy is unclear. Time-sequenced administration of growth factors and chemotherapy was hypothesized to protect normal hematopoietic precursors during chemotherapy administration. In one study, G-CSF treatment given 36 hours after and ending 48 hours before 4 weekly chemotherapy administrations resulted in an overall shorter treatment duration compared with controls (134 vs. 153 days from induction through consolidation; P = .005). 40 This strategy showed a nonsignificant difference in severe infections (9% vs. 21%), fewer symptoms associated with infections, and a reduction in the median number of days of febrile neutropenia. However, another study that administered G-CSF concurrently with chemotherapy had similar results with fewer delays in chemotherapy.
23
A few studies have shown a benefit in clinical outcomes, including a decrease in documented infections, 41, 42 rates of fevers, 41, 42 and infectious symptoms with growth factor support, regardless of the growth factor schedule in relation to chemotherapy.
40 GM-CSF support was associated with decreased induction deaths in one study of relapsed ALL, but this was not statistically significant (6% vs. 21%; P = .08). 43 Unfortunately, all studies except one have shown that growth factor support has no impact on OS or DFS. This small study of 64 patients with a relatively short follow-up of 2 years reported a higher overall survival (59% vs. 27%; P = .04) and a lower relapse rate which was not statistically significant (32% vs. 60%; P = .19).
40

Conclusions
Evidence suggests that growth factors are helpful in reducing the duration and severity of neutropenia for individuals during induction and consolidation for AML and ALL. No evidence suggests that they are detrimental or contribute to inferior clinical outcomes, either in a priming strategy for AML or administered as part of supportive care after chemotherapy in AML or ALL. However, they are costly and little evidence suggests that a shorter duration of neutropenia results in a clinically significant benefit in acute leukemias. In solid tumors, neutropenia is usually due to chemotherapy, not to the disease, and has a shorter duration than in leukemia. As a result, growth factor support may obviate the risks of neutropenia in solid tumor patients. In contrast, patients with acute leukemia oftentimes present with neutropenia, which becomes more profound following chemotherapy and persists for many weeks. As such, multiple, large randomized studies have demonstrated that a shorter duration of neutropenia does not translate into end points of OS in AML. As a consequence, there is no clear consensus as to their use in AML. Given the lack of adverse data associated with their use, growth factor support in AML is reasonable in patients older than 60 or those who may not tolerate chemotherapy well. Furthermore, because of the lack of evidence demonstrating that they stimulate leukemic growth, they may be of use as part of supportive care for those undergoing consolidation chemotherapy. Numerous studies have shown no clear advantage to priming with growth factors before and during chemotherapy for AML. In ALL, randomized controlled trials have shown that growth factor support results in a faster neutrophil recovery, which has translated into modest improvements in clinical end points, such as induction death rates, incidence of severe infections, and dose intensity of chemotherapy.
